EP0804604A2 - Verfahren zum verbesseren der screening-leistungsfähigkeit in fusionierten zellen - Google Patents

Verfahren zum verbesseren der screening-leistungsfähigkeit in fusionierten zellen

Info

Publication number
EP0804604A2
EP0804604A2 EP96905259A EP96905259A EP0804604A2 EP 0804604 A2 EP0804604 A2 EP 0804604A2 EP 96905259 A EP96905259 A EP 96905259A EP 96905259 A EP96905259 A EP 96905259A EP 0804604 A2 EP0804604 A2 EP 0804604A2
Authority
EP
European Patent Office
Prior art keywords
cells
fusion
human
cell line
yac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96905259A
Other languages
English (en)
French (fr)
Inventor
Aya Jakobovitz
Margaret C. Hardy
Larry Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Fremont Inc
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of EP0804604A2 publication Critical patent/EP0804604A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP96905259A 1995-01-20 1996-01-19 Verfahren zum verbesseren der screening-leistungsfähigkeit in fusionierten zellen Withdrawn EP0804604A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37627995A 1995-01-20 1995-01-20
US376279 1995-01-20
PCT/US1996/001169 WO1996022380A2 (en) 1995-01-20 1996-01-19 Method to improve screening efficiency in fused cells

Publications (1)

Publication Number Publication Date
EP0804604A2 true EP0804604A2 (de) 1997-11-05

Family

ID=23484361

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96905259A Withdrawn EP0804604A2 (de) 1995-01-20 1996-01-19 Verfahren zum verbesseren der screening-leistungsfähigkeit in fusionierten zellen

Country Status (6)

Country Link
EP (1) EP0804604A2 (de)
JP (1) JPH10512449A (de)
KR (1) KR19980701536A (de)
AU (1) AU4906696A (de)
CA (1) CA2210986A1 (de)
WO (1) WO1996022380A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1212422B1 (de) 1999-08-24 2007-02-21 Medarex, Inc. Humane antikörper gegen ctla-4 und deren verwendungen
DK2319301T3 (en) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
EP1954311A4 (de) 2005-12-07 2009-12-23 Medarex Inc Ctla-4-antikörper-dosierungseskalationstherapien

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2637613B1 (fr) * 1987-06-19 1991-09-27 Transgene Sa Procede de preparation de lignees cellulaires stables pour la production de proteines determinees, a partir d'animaux transgeniques; lignees cellulaires tumorales et proteines obtenues
JP3008208B2 (ja) * 1990-06-01 2000-02-14 武田薬品工業株式会社 新規ハイブリドーマ，その製造法および生理活性物質の製造法
CA2140638C (en) * 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9622380A2 *

Also Published As

Publication number Publication date
WO1996022380A2 (en) 1996-07-25
JPH10512449A (ja) 1998-12-02
AU4906696A (en) 1996-08-07
CA2210986A1 (en) 1996-07-25
KR19980701536A (ko) 1998-05-15
WO1996022380A3 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
AU675661B2 (en) Generation of xenogeneic antibodies
US6114598A (en) Generation of xenogeneic antibodies
JP2938569B2 (ja) 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US6162963A (en) Generation of Xenogenetic antibodies
US8110671B2 (en) Isolated human chromosome 14 fragment encoding immunoglobulin genes
JP2022071051A (ja) Ａｄａｍ６マウス
CA2468565C (en) Transgenic animals bearing human iglambda light chain genes
CN107602696B (zh) 人源化的通用轻链小鼠
KR100855998B1 (ko) 비동족형 스위치 영역에 의해 인간 항체의 특정 이소타입을 생산하는 트랜스제닉 동물
AU5702298A (en) Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
CN101002549A (zh) 能够生产异源抗体的转基因非人动物
JPH11206387A (ja) 異種免疫グロブリンを作る方法及びそのためのトランスジェニックマウス
EP0804604A2 (de) Verfahren zum verbesseren der screening-leistungsfähigkeit in fusionierten zellen
CA2702329A1 (en) Generation of xenogeneic antibodies
NZ627211B2 (en) Humanized light chain mice

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970813

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19971017

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABGENIX, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990730